Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Many patients with HR+, HER2− early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few ye...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Johnston, Stephen R. D., Harbeck, Nadia, Hegg, Roberto, Toi, Masakazu, Martin, Miguel, Shao, Zhi Min, Zhang, Qing Yuan, Martinez Rodriguez, Jorge Luis, Campone, Mario, Hamilton, Erika, Sohn, Joohyuk, Guarneri, Valentina, Okada, Morihito, Boyle, Frances, Neven, Patrick, Cortés, Javier, Huober, Jens, Wardley, Andrew, Tolaney, Sara M., Cicin, Irfan, Smith, Ian C., Frenzel, Martin, Headley, Desirée, Wei, Ran, San Antonio, Belen, Hulstijn, Maarten, Cox, Joanne, O’Shaughnessy, Joyce, Rastogi, Priya
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2020
Matèries:
RAPID COMMUNICATIONS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768339/
https://ncbi.nlm.nih.gov/pubmed/32954927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02514
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars